Oticon Adds Zeal, Intent, and Verit Hearing Aids to VA Contract
The new additions include an in-the-ear rechargeable, a flexible miniBTE R, and a zinc-air miniRITE T model designed for government services audiologists and their patients.
Read MoreThe new additions include an in-the-ear rechargeable, a flexible miniBTE R, and a zinc-air miniRITE T model designed for government services audiologists and their patients.
Read MoreThe addition of CIC Rechargeable Custom IX, Silk IX, and Active Pro IX completes the company’s Integrated Xperience platform for the VA, DoD, and IHS.
Read MoreAt AAA 2026, a panel of industry executives explored the impact of artificial intelligence, a looming talent shortage, and the critical need to reframe hearing loss as a core health issue.
Read MoreThe AI-driven software analyzes otoscopy videos to detect eardrum bulging, establishing a new regulatory category for ENT diagnostic aids.
Read MoreThe company plans a clinical trial for its CIL001 drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET.
Read MoreThe award highlights the discreet hearing aid’s design, innovation, and user-centered features.
Read MoreThe resolution acknowledges the organization’s contributions to the hearing aid specialist profession.
Read MoreA multicenter study found a one-time treatment targeting the OTOF gene restored hearing in most participants, with effects lasting up to 2.5 years.
Read MoreThe in-the-ear hearing aid has now received five industry awards for its design and performance since its August 2025 launch.
Read MoreThe company’s OtoKiosk digital audiometer and Amplifon App were recognized by the UX Design Awards and iF Design Awards for user experience and innovation.
Read MoreThe award from the Edge AI + Vision Alliance recognizes the Omega AI for its on-device intelligence and real-time processing capabilities.
Read MoreThe move unifies existing and future audiology and vestibular diagnostic solutions under the legacy brand name.
Read MoreIn a pivotal trial, 42% of participants achieved normal hearing using the gene therapy indicated for pediatric and adult patients with severe-to-profound hearing loss due to biallelic OTOF gene variants.
Read MoreThe sponsorship anchors the new “Hear to Win” campaign, bringing hearing health education and technology demonstrations to pickleball events nationwide.
Read MoreEuropean-developed Freequency, backed by key psychology experts, launches US pilot program at AAA 2026.
Read More